Table 3.
The reported clinical trials using MSCs from AT, BM, and UC in the treatment of the endocrinological disorder, reproductive disease, and skin healing
| Year | Type of disease | Cell source | No. of treated patients | Efficacy |
|---|---|---|---|---|
| 2014265 | Type 1 diabetes | BM | 9 | - No significant improvement compared to control group in HbA1c, insulin doses per kilogram, fasting C-peptide |
| - 3/9 MSC-treated patients decreased their peak C-peptide or AUC response to the MMTT while 8/9 patients decreased in peak C-peptide, and 7/9 decreased in AUC response in the control group | ||||
| 2021266 | Type 1 diabetes | AD | 7 | Significant improvement compared to before transplantation in basal C-peptide and HbA1C |
| 2013268 | Type 1 diabetes | WJ | 15 | Significant improvement over the control group in HbA1c and fasting C-peptide |
| 2015269 | Type 1 diabetes | WJ + BM | 21 | The metabolic measures improved in treated patients: |
| + AUC C-Pep increased 105.7% (P = 0.00012); | ||||
| + insulin area under the curve increased 49.3% (P = 0.01) | ||||
| + HbA1c decreased 12.6% (P < 0.01) | ||||
| + Fasting glycemia decreased 24.4% (P < 0.002) | ||||
| + Daily insulin requirements decreased 29.2% (P = 0.001) | ||||
| 2021271 | Type 2 diabetes | BM | 25 | A slight reduction in HbA1c levels was observed in the first 3 months after administration, but the level returned to normal after 6 months and even increased |
| 2005288 | Skin burns | BM | 1 | The improvement in vascularization at the wound site and reduced coarse cicatrices |
| 2012290 | Skin burns | BM | 1 | The areas treated with autologous BM-MSCs combined with transplantation of split skin were less likely to have contraction of the skin grafts. |
| 2008291 | Skin wounds | BM | 20 | The wound mostly healed in 18 of the 20 patients showed the BM-MSCs transplantation effectively |
| 2017292 | Skin burns | BM-MSC & UC-MSC | 40 | The significantly improved rate of healing in both BM-MSC and UC-MSC groups as compared to traditionally treated group in percent of burn extent (%), hospitalization time. |
| 2018280 | Premature ovarian insufficiency | BM-MSC | 1 | - The AMH level improved from 0.4 to 0.9 ng/mL |
| - The improvement of follicular regeneration resulted in a successful pregnancy followed by the delivery of a healthy infant | ||||
| 2020281 | Premature ovarian failure | BM-MSC | 2 | The increase in baseline estrogen levels and amelioration of menopausal symptoms |
| 2018422 | Premature ovarian insufficiency | UC-MSC | 14 | The elevated estradiol concentrations, improved follicular development, and increased number of antral follicles |
| 2016488 | Premature ovarian insufficiency | BM-MSC | 10 | The improvement in Edessy ovarian reserve score (EORS) and increased pregnancy capacity |
| 2016489 | Premature ovarian insufficiency | BM-MSC | 30 | 86.7% of patients showed a fall in FSH levels and a rise in estrogen and AMH levels after 4 weeks of injection |
| 2018283 | Premature ovarian insufficiency | BM-MSC | 15 | - The significant improvement in AFC and AMH after treatment. |
| - Increased the number of stimulable antral follicles and oocytes | ||||
| - Ovarian function improved in 81.3% of women |
AFC antral follicle count, AMH anti-Müllerian hormone, AUC area under the curve (oral glucose tolerance test), FSH follicle-stimulating hormone, HbA1C hemoglobin A1C, MMTT mixed-meal tolerance test